THERAVANCE BIOPHARMA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.165 USD | +0.71% |
|
-3.25% | -19.17% |
| May. 13 | Theravance Narrows Q1 Loss as Revenue Rises; Shares Rise After-hours | MT |
| May. 13 | Transcript : Theravance Biopharma, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Presenter SpeechRick Winningham (Executives)Good afternoon, and welcome to the Theravance Biop...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Investor Meeting - Key Openion Leader
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
9.1
USD
Average target price
15.4
USD
Spread / Average Target
+69.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.17% | 443M | |
| +37.94% | 705B | |
| +32.82% | 583B | |
| -3.63% | 364B | |
| +19.98% | 332B | |
| +5.42% | 291B | |
| +16.64% | 238B | |
| -4.13% | 210B | |
| +10.63% | 209B | |
| +9.50% | 169B |
- Stock Market
- Equities
- TBPH Stock
- News Theravance Biopharma, Inc.
- Transcript : Theravance Biopharma, Inc. - Shareholder/Analyst Call